Agents Targeted Against PSMA for Prostate Cancer

Commentary
Article

Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.

Clinical Pearls

Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.

  • As resistance to AR-targeted therapy develops, PSMA expression will increase in many patients. An agent targeted against PSMA could be added in at this time.
  • PSMA-targeted therapy could also potentially be used in combination with AR-targeted therapy.
  • Both AR- and PSMA-targeted therapies are being investigated in clinical trials and are already making an impact.
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content